BIO International Convention 2014 Preview - BIO and World-Wide Intellectual Property Protection

by McDonnell Boehnen Hulbert & Berghoff LLP
Contact

BIO International ConventionThe 2014 BIO International Convention begins next week in San Diego.  If you are planning on attending, you probably already know that the amount of information and opportunities available at BIO can be daunting.  Therefore, over the next week, Patent Docs will be highlighting a few sessions or other opportunities, in thematic fashion, to help you navigate your way through the convention.  For example, today, in honor of the World Cup, we focus on the "International" aspect of the convention by highlighting opportunities for those attendees that wish to compare intellectual property issues around the globe.  Of course, Patent Docs authors and contributors will be present at BIO as part of the MBHB contingent, and Patent Docs readers are encouraged to stop by the MBHB booth (#1337) to discuss these sessions (or whatever other topic is of interest to you).

As any patent practitioner in the biotech and pharmaceutical space is aware, the various intellectual property protections available worldwide, with the varying requirements for patentability, can create a landmine for the unwary.  For example, some countries encourage early filing to avoid potential prior art issues, thereby providing for quicker public access to the technology disclosed.  Others, unfortunately, have heightened disclosure requirements, which counsels against filing until sufficient data is obtained.  Moreover, the various countries' policies towards follow-on biologics or personalized medicine with accompanying diagnostics create a tension between disclosure in order to obtain patent protection and non-disclosure in order to maintain trade secrets.  Several sessions across various tracks and forums will address some of these most difficult issues.

First on our list, the Emerging Opportunities in Global Markets Forum will present "Predictions for the Future: Biopharmaceuticals and Exclusivity" on Thursday, June 26 at 11:00 AM to 12:00 noon.  The panel involved in this presentation will provide their perspective on the issue of follow-on biopharmaceuticals in various leading markets.  Pathways for the approval of such drugs are either very new or still forming.  Therefore, as the description of the session explains, decisions must be made in view of an uncertain legal and regulatory landscape, especially with regard to the intellectual property or regulatory exclusivity of these products.  The panel will explore the state of the global regulatory pathways, and how they present both opportunity and risk.  In addition, they will explain how organizations are dealing with new IP laws, and how these biopharmaceutical regulatory and IP systems will change strategies going forward.  This panel includes the Associate General Counsel of BIO, Hans Sauer; as well as Sherry Knowles, currently of Knowles Intellectual Property Strategies; Stephen Auten, Partner at Taft and renowned for his LinkedIn Hatch-Waxman ANDA Litigation Forum; and James Shehan, Counsel at Hyman, Phelps & McNamara, P.C.  The session will be moderated by Len Smith, currently General Counsel and Vice President of Heliae Development, LLC.

Another area of significant interest for patent professionals practicing on a global scale is the concerns regarding disclosure requirements for patent application in different countries.  The problem becomes concrete when applicants need to decide whether to file an application with minimal data as soon as possible to minimize the changes of invalidating prior art, or to wait for additional data because of heightened disclosure requirements.  Famously, the Canadian courts have invalidated at least two of Eli Lilly's successful drugs, as well as many other companies' pharmaceuticals, because they did not meet the "promise doctrine" for utility.  In response, Eli Lilly has filed a Notice of Arbitration pursuant to the provision in the North American Free Trade Agreement (or NAFTA).  In contrast to the restrictions placed on the post-filing evidence to support utility in Canada and China, the U.S. and Europe allow such evidence for already-filed applications.  A session of the Intellectual Property track entitled "Show Me the Data!  Threshold Patent Application Disclosure Requirements & Post-Filing Evidence Admissibility in the U.S., Europe, Canada & China" will explore how the patent offices in these countries and regions treat post-filing evidence, and identify strategies of preparing applications in view of these disparate policies.  In addition, they will examine what impact the timing and availability of data acquisition has on filing applications in different jurisdictions worldwide.  The panelists will be Arvie Anderson, Assistant General Patent Counsel at Eli Lilly and Company; Patrick Kierans, Senior Partner at Norton Rose, LLP in Toronto, Canada; Wen Cao, Patent Attorney with NTD Intellectual Property Attorneys in Shanghai, China; and Ute Kilger, Partner at Boehmert & Boehmert in München, Germany.  The session will be moderated by Ed Haug, Managing Partner of Frommer Lawrence & Haug LLP, and will take place on Tuesday, June 24 at 4:15 PM to 5:15 PM.

As a final example, the Personalized Medicine & Diagnostic Forum with be presenting "Navigating the Intellectual Property Minefield to Protect Personalized Medicine Innovations Worldwide" on Thursday, June 26 at 1:00 PM to 2:00 PM.  As pointed out in the description of this session, recent legal decisions and local policies have presented obstacles for obtaining IP protection involving personalized medicine.  However, numerous drugs are being developed with companion diagnostics.  Without sufficient IP protection to justify investments, many such therapies may never reach the market.  This panel of U.S. and European attorneys will identify the primary IP obstacles and offer strategies for generating adequate IP protection for personalized medicine innovations.  In addition, they will explore the impact that this IP will have for business and investment decisions in the major market countries.  The panel includes Hans-Rainer Jaenichen, Partner at Vossius & Partner; Shihong Nicolaou, Intellectual Property Manager of the Technology Transfer Office, U.C.S.D; and Scott Rittman, Associate Chief Intellectual Property Counsel, Becton, Dickinson and Company.  The panel will be moderated by Ned Israelsen, Managing Partner of Knobbe Martens Olson & Bear, LLP.

Be on the look-out for the next installment of BIO 2014 previews in the next few days.

 

 

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McDonnell Boehnen Hulbert & Berghoff LLP | Attorney Advertising

Written by:

McDonnell Boehnen Hulbert & Berghoff LLP
Contact
more
less

McDonnell Boehnen Hulbert & Berghoff LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.